174 related articles for article (PubMed ID: 38741565)
21. Efficacy and Safety of Domperidone in Combination with Proton Pump Inhibitors in Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Zamani NF; Sjahid AS; Tuan Kamauzaman TH; Lee YY; Islam MA
J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36142915
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Laparoscopic Nissen Fundoplication vs Transoral Incisionless Fundoplication or Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-analysis.
Richter JE; Kumar A; Lipka S; Miladinovic B; Velanovich V
Gastroenterology; 2018 Apr; 154(5):1298-1308.e7. PubMed ID: 29305934
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection.
Teng M; Khoo AL; Zhao YJ; Lin L; Lim BP; Wu TS; Dan YY
J Clin Pharm Ther; 2015 Aug; 40(4):368-75. PubMed ID: 25893507
[TBL] [Abstract][Full Text] [Related]
24. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis.
Sun S; Cui Z; Zhou M; Li R; Li H; Zhang S; Ba Y; Cheng G
Neurogastroenterol Motil; 2017 Feb; 29(2):. PubMed ID: 27577963
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of transoral incisionless fundoplication for refractory gastroesophageal reflux disease: a systematic review and meta-analysis.
McCarty TR; Itidiare M; Njei B; Rustagi T
Endoscopy; 2018 Jul; 50(7):708-725. PubMed ID: 29625507
[TBL] [Abstract][Full Text] [Related]
26. Magnetic sphincter augmentation in treating refractory gastroesophageal reflux disease: A systematic review and meta-analysis.
Zhuang QJ; Tan ND; Chen SF; Zhang MY; Xiao YL
J Dig Dis; 2021 Dec; 22(12):695-705. PubMed ID: 34693633
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of alginate formulations in patients with gastroesophageal reflux disease: a systematic review and meta-analysis of randomized controlled trials.
Zhao CX; Wang JW; Gong M
Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11845-11857. PubMed ID: 33275256
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of tegoprazan in the treatment of gastroesophageal reflux disease: A protocol for meta-analysis and systematic review.
Zheng H; Yuan S; Liu J
PLoS One; 2024; 19(5):e0302450. PubMed ID: 38696509
[TBL] [Abstract][Full Text] [Related]
29. Proton pump inhibitors for functional dyspepsia.
Pinto-Sanchez MI; Yuan Y; Bercik P; Moayyedi P
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011194. PubMed ID: 28271513
[TBL] [Abstract][Full Text] [Related]
30. Fundoplication versus oral proton pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis of randomized clinical trials.
Tristão LS; Tustumi F; Tavares G; Bernardo WM
Esophagus; 2021 Apr; 18(2):173-180. PubMed ID: 33527310
[TBL] [Abstract][Full Text] [Related]
31. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis.
Leiman DA; Riff BP; Morgan S; Metz DC; Falk GW; French B; Umscheid CA; Lewis JD
Dis Esophagus; 2017 May; 30(5):1-9. PubMed ID: 28375448
[TBL] [Abstract][Full Text] [Related]
32. Potassium-competitive acid blockers and gastroesophageal reflux disease.
Leowattana W; Leowattana T
World J Gastroenterol; 2022 Jul; 28(28):3608-3619. PubMed ID: 36161043
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy of Yukgunja-tang combined with a proton pump inhibitor for refractory gastroesophageal reflux disease: study protocol for randomized, double-blind, double-dummy clinical trial.
Ha NY; Kim JW; Kim J
BMC Complement Med Ther; 2023 Dec; 23(1):444. PubMed ID: 38062418
[TBL] [Abstract][Full Text] [Related]
34. Short-term treatment of gastroesophageal reflux disease.
van Pinxteren B; Numans ME; Lau J; de Wit NJ; Hungin AP; Bonis PA
J Gen Intern Med; 2003 Sep; 18(9):755-63. PubMed ID: 12950485
[TBL] [Abstract][Full Text] [Related]
35. Comparative safety and efficacy of proton pump inhibitors in paediatric gastroesophageal reflux disease.
Kierkus J; Oracz G; Korczowski B; Szymanska E; Wiernicka A; Woynarowski M
Drug Saf; 2014 May; 37(5):309-16. PubMed ID: 24706290
[TBL] [Abstract][Full Text] [Related]
36. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease.
Scarpignato C; Hunt RH
Curr Opin Gastroenterol; 2019 Jul; 35(4):344-355. PubMed ID: 31045597
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
[TBL] [Abstract][Full Text] [Related]
38. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
Freedberg DE; Kim LS; Yang YX
Gastroenterology; 2017 Mar; 152(4):706-715. PubMed ID: 28257716
[TBL] [Abstract][Full Text] [Related]
39. The pharmacotherapeutic management of gastroesophageal reflux disease (GERD).
Chapelle N; Ben Ghezala I; Barkun A; Bardou M
Expert Opin Pharmacother; 2021 Feb; 22(2):219-227. PubMed ID: 32893683
[TBL] [Abstract][Full Text] [Related]
40. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
